Double-Drug attack on cholesterol could help Statin-Intolerant patients
NCT ID NCT07581808
First seen May 13, 2026 · Last updated May 22, 2026 · Updated 1 time
Summary
This study tests whether combining two different cholesterol-lowering drugs (inclisiran and alirocumab) works better than either drug alone. About 60 adults with high heart risk who cannot take statins will be assigned to one of three groups and followed for 9 months. The goal is to see if the combo lowers 'bad' cholesterol more effectively and safely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Centre Ljubljana
Ljubljana, 1000, Slovenia
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.